CRISPR Therapeutics AG
Open
$49.84
Prev. Close
$49.85
High
$49.94
Low
$49.78
Market Snapshot
$4.78B
-8.4
-4.35
$37.31M
393
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Recently from Cashu
CRISPR Therapeutics AG Pursues Growth with Strategic Corporate Moves and Gene Editing Innovations
CRISPR Therapeutics AG (Ticker: CRSP) makes strategic corporate moves to enhance its growth potential in the competitive biopharmaceutical landscape. The company is proactively adapting to market dyna…
CRISPR Therapeutics Gains Momentum with Casgevy Adoption and Improved Q1 2026 Performance
CRISPR Therapeutics AG (Ticker: CRSP) is making significant strides in the gene editing sector, primarily through its innovative product Casgevy. Recent reports indicate that the company is witnessing…
CRISPR Therapeutics AG Achieves Financial Progress Amid Advancements in Gene-Editing Portfolio
CRISPR Therapeutics AG (Ticker: CRSP) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, the co…
CRISPR Therapeutics Expands Growth Strategy with New Product Launches and Promising Pipeline Programs
CRISPR Therapeutics AG (Ticker: CRSP) is making significant strides in its growth strategy, as recently articulated by CEO Sam Kulkarni. The company is moving into a 'second phase' following the succe…